Expect great science.
It’s in our DNA.
ExcellGene’s reliable process and exceptional CHO cell hosts are the result of over twenty years of innovation and fine-tuning.
Experts in CHO and HEK-293
Our services
Our services in stable cell line development and recombinant protein manufacturing cover the value chain – from DNA construction and transfection to CHO and HEK process development, to large-scale protein production. Our cGMP compliant facility enables the generation of Master Cell Banks and Master Working Banks (MCB, MWB).
ExcellGene’s reliable process and exceptional CHO cell host are the result of over twenty years of innovation and fine-tuning. Here’s what you can expect.
Cell line development
Our Cell Line Development and Process Development services offer comprehensive solutions for the development of biologics, including generation of cGMP master cell banks and tox batches. We leverage our expertise to generate high-yield and stable cell lines, optimizing upstream and downstream processes to ensure the scalability and quality of your product. We provide early manufacturability assessments with up to 500 mg of protein from a single batch for feasibility studies.
Biosimilars development
ExcellGene is committed to advancing biosimilars development. Our experienced team specializes in the development of the best, yield competitive cell lines and production of biosimilar candidates, following stringent regulatory guidelines. We aim to provide cost-effective alternatives that meet the highest standards of biosimilarity.
Licensing
Our Licensing opportunities enable partners to leverage our innovative technologies and expertise in biopharmaceutical development. We offer flexible licensing options that allow for the utilization of our proprietary platforms and know-how, including CHOExpress®, HEKExpress®, HEKzeroT®.
Gene therapy
Our Gene Therapy solutions encompass viral vector production, including AAVs, using our advanced cell hosts. With our expertise in cell line development and bioprocessing, we enable efficient and scalable production of viral vectors for gene therapy applications.
Partner with us to advance your gene therapy programs with reliable and high-quality viral vectors with over 40% capsid filling before DSP.
High Titers
Up to 14 g/L, fully chemically defined process
Speedy timelines
high-yield clone in 8 weeks
Diverse protein formats
Robust cells for scalable processes
10ml, 1.5L. 10L 40L, 200L, 1000L
We serve biotech and pharmaceutical companies and provide solutions worldwide
We’ve provided biologics and biotech solutions to hundreds of clients, including 6 of the top 10 pharmaceutical firms, biotech companies, contract research organizations and academic institutions.
We serve biotech and pharmaceutical companies and provide solutions worldwide
We’ve provided biologics and biotech solutions to hundreds of clients, including 6 of the top 10 pharmaceutical firms, biotech companies, contract research organizations and academic institutions.
Recents posts
On-demand webinar
Newly Available on-demand webinar! How to quantify AAV particle production from transfected HEK cellsJoin ExcellGene SA, a company providing AAV production processes and develops such processes for its clients, in a free webinar. Dr. Yoann Saucereau, a research...
A superior HEK cell line for AAV production
A superior HEK cell line for AAV productionWriter's Insight Derived from ExcellGene's HEKExpress® cells, a widely used cell system known for its transient and stable protein expression, a new host system with superior performance has been developed. This innovative...
EXCELLGENE, Switzerland, and LOTTE BIOLOGICS, South Korea, Announce a Collaboration for Cell Line Development and Manufacturing of Biologics.
EXCELLGENE, Switzerland, and LOTTE BIOLOGICS, South Korea, Announce a Collaboration for Cell Line Development and Manufacturing of Biologics.PRESS RELEASETues 4th April, 2023LOTTE BIOLOGICS and EXCELLGENE today announced the signing of a Memorandum of Understanding to...